Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122562) titled 'QUEEN-APPLE: A single-arm, multicenter, prospective phase II clinical study of QL1706 (iparomlimab and tuvonralimab) in combination with anlotinib hydrochloride and nab-paclitaxel as first-line treatment for advanced triple-negative breast cancer' on April 15.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Jiangsu Cancer Hospital
Condition:
Triple-negative breast cancer
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-20
Target Sample Size: Treatment group:34;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/sh...